Zanzalintinib is an investigational oral agent that inhibits tyrosine kinase receptors associated with cancer growth, including TYRO3, VEGF, MET, AXL, and MER.

The FDA application is supported by data from the Phase 3 evERA Breast Cancer study. The trial results showed that the combination of giredestrant and Afinitor reduced the risk of disease progression ...

Immunotherapy given before or after surgery is increasingly used across several cancer areas. In an article published in the Journal of Internal Medicine, researchers at Karolinska Institutet present ...

Combined epigenetic and immune checkpoint therapy altered the tumour microenvironment in platinum-resistant ovarian cancer.

Phase 3 trial data show datopotamab deruxtecan reduces the risk of disease progression or death in patients with metastatic TNBC.

But an association with improved overall survival failed to reach statistical significance ...

Exercise can counter the detrimental effects of cancer treatment, such as heart and nerve damage and brain fog, suggests an overarching review of the existing pooled data analyses of the most recent ...

A comprehensive analysis of clinical and preclinical data reveals that GLP-1 receptor agonists, previously suspected of increasing cancer risk, are generally safe and may even reduce the incidence of ...

Please provide your email address to receive an email when new articles are posted on . Cancer therapy may reduce cardiorespiratory fitness, as measured by peak VO 2, for years after treatment.